WO2011007552A1 - Bad breath-removing agent - Google Patents
Bad breath-removing agent Download PDFInfo
- Publication number
- WO2011007552A1 WO2011007552A1 PCT/JP2010/004531 JP2010004531W WO2011007552A1 WO 2011007552 A1 WO2011007552 A1 WO 2011007552A1 JP 2010004531 W JP2010004531 W JP 2010004531W WO 2011007552 A1 WO2011007552 A1 WO 2011007552A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- sugar alcohol
- bad breath
- lactitol
- maltitol
- active ingredient
- Prior art date
Links
- 206010006326 Breath odour Diseases 0.000 title claims abstract description 41
- 150000005846 sugar alcohols Chemical class 0.000 claims abstract description 42
- 239000000832 lactitol Substances 0.000 claims abstract description 32
- 235000010448 lactitol Nutrition 0.000 claims abstract description 32
- VQHSOMBJVWLPSR-JVCRWLNRSA-N lactitol Chemical compound OC[C@H](O)[C@@H](O)[C@@H]([C@H](O)CO)O[C@@H]1O[C@H](CO)[C@H](O)[C@H](O)[C@H]1O VQHSOMBJVWLPSR-JVCRWLNRSA-N 0.000 claims abstract description 32
- 229960003451 lactitol Drugs 0.000 claims abstract description 32
- 238000004519 manufacturing process Methods 0.000 claims abstract description 17
- 239000004480 active ingredient Substances 0.000 claims abstract description 16
- 230000002401 inhibitory effect Effects 0.000 claims abstract description 14
- 150000003464 sulfur compounds Chemical class 0.000 claims abstract description 10
- 239000003795 chemical substances by application Substances 0.000 claims abstract description 8
- 239000000845 maltitol Substances 0.000 claims description 33
- VQHSOMBJVWLPSR-WUJBLJFYSA-N maltitol Chemical compound OC[C@H](O)[C@@H](O)[C@@H]([C@H](O)CO)O[C@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O VQHSOMBJVWLPSR-WUJBLJFYSA-N 0.000 claims description 33
- 235000010449 maltitol Nutrition 0.000 claims description 33
- 229940035436 maltitol Drugs 0.000 claims description 33
- 230000037353 metabolic pathway Effects 0.000 claims description 18
- XUJNEKJLAYXESH-REOHCLBHSA-N L-Cysteine Chemical compound SC[C@H](N)C(O)=O XUJNEKJLAYXESH-REOHCLBHSA-N 0.000 claims description 16
- FFEARJCKVFRZRR-BYPYZUCNSA-N L-methionine Chemical compound CSCC[C@H](N)C(O)=O FFEARJCKVFRZRR-BYPYZUCNSA-N 0.000 claims description 15
- XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 claims description 14
- 235000018417 cysteine Nutrition 0.000 claims description 14
- 229930182817 methionine Natural products 0.000 claims description 14
- 239000000606 toothpaste Substances 0.000 claims description 9
- 229940034610 toothpaste Drugs 0.000 claims description 9
- 235000013305 food Nutrition 0.000 claims description 7
- 239000002324 mouth wash Substances 0.000 claims description 7
- 229940051866 mouthwash Drugs 0.000 claims description 7
- 239000003112 inhibitor Substances 0.000 claims description 6
- 239000007937 lozenge Substances 0.000 claims description 5
- -1 inhalant Substances 0.000 claims description 4
- 230000002940 repellent Effects 0.000 claims 1
- 239000005871 repellent Substances 0.000 claims 1
- LSDPWZHWYPCBBB-UHFFFAOYSA-N Methanethiol Chemical compound SC LSDPWZHWYPCBBB-UHFFFAOYSA-N 0.000 description 36
- TVXBFESIOXBWNM-UHFFFAOYSA-N Xylitol Natural products OCCC(O)C(O)C(O)CCO TVXBFESIOXBWNM-UHFFFAOYSA-N 0.000 description 20
- HEBKCHPVOIAQTA-UHFFFAOYSA-N meso ribitol Natural products OCC(O)C(O)C(O)CO HEBKCHPVOIAQTA-UHFFFAOYSA-N 0.000 description 20
- 238000012360 testing method Methods 0.000 description 20
- 239000000811 xylitol Substances 0.000 description 20
- 235000010447 xylitol Nutrition 0.000 description 20
- 229960002675 xylitol Drugs 0.000 description 20
- HEBKCHPVOIAQTA-SCDXWVJYSA-N xylitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)CO HEBKCHPVOIAQTA-SCDXWVJYSA-N 0.000 description 20
- 230000000694 effects Effects 0.000 description 19
- 239000004386 Erythritol Substances 0.000 description 16
- UNXHWFMMPAWVPI-UHFFFAOYSA-N Erythritol Natural products OCC(O)C(O)CO UNXHWFMMPAWVPI-UHFFFAOYSA-N 0.000 description 16
- 229930006000 Sucrose Natural products 0.000 description 16
- UNXHWFMMPAWVPI-ZXZARUISSA-N erythritol Chemical compound OC[C@H](O)[C@H](O)CO UNXHWFMMPAWVPI-ZXZARUISSA-N 0.000 description 16
- 235000019414 erythritol Nutrition 0.000 description 16
- 229940009714 erythritol Drugs 0.000 description 16
- 239000000203 mixture Substances 0.000 description 16
- 239000005720 sucrose Substances 0.000 description 16
- RWSOTUBLDIXVET-UHFFFAOYSA-N Dihydrogen sulfide Chemical compound S RWSOTUBLDIXVET-UHFFFAOYSA-N 0.000 description 15
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 15
- 229910000037 hydrogen sulfide Inorganic materials 0.000 description 15
- 235000009508 confectionery Nutrition 0.000 description 14
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 13
- 229960002433 cysteine Drugs 0.000 description 12
- 229960004452 methionine Drugs 0.000 description 12
- 210000000214 mouth Anatomy 0.000 description 12
- 239000000243 solution Substances 0.000 description 11
- 241000605862 Porphyromonas gingivalis Species 0.000 description 9
- 235000015218 chewing gum Nutrition 0.000 description 9
- 229940112822 chewing gum Drugs 0.000 description 9
- 239000003205 fragrance Substances 0.000 description 9
- 230000005764 inhibitory process Effects 0.000 description 9
- 230000007935 neutral effect Effects 0.000 description 9
- 241000605986 Fusobacterium nucleatum Species 0.000 description 8
- 210000003296 saliva Anatomy 0.000 description 8
- 238000006243 chemical reaction Methods 0.000 description 7
- 238000009472 formulation Methods 0.000 description 7
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 6
- 230000001580 bacterial effect Effects 0.000 description 6
- 230000008859 change Effects 0.000 description 6
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 6
- 238000004817 gas chromatography Methods 0.000 description 6
- 238000011534 incubation Methods 0.000 description 6
- 230000001953 sensory effect Effects 0.000 description 6
- QMMFVYPAHWMCMS-UHFFFAOYSA-N Dimethyl sulfide Chemical compound CSC QMMFVYPAHWMCMS-UHFFFAOYSA-N 0.000 description 5
- 239000007789 gas Substances 0.000 description 5
- 230000002829 reductive effect Effects 0.000 description 5
- 239000003826 tablet Substances 0.000 description 5
- 241000894006 Bacteria Species 0.000 description 4
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 4
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 4
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 4
- 235000013361 beverage Nutrition 0.000 description 4
- 238000011156 evaluation Methods 0.000 description 4
- 235000015110 jellies Nutrition 0.000 description 4
- 239000008274 jelly Substances 0.000 description 4
- 238000002360 preparation method Methods 0.000 description 4
- 239000012488 sample solution Substances 0.000 description 4
- 239000000600 sorbitol Substances 0.000 description 4
- 235000010356 sorbitol Nutrition 0.000 description 4
- JIAARYAFYJHUJI-UHFFFAOYSA-L zinc dichloride Chemical compound [Cl-].[Cl-].[Zn+2] JIAARYAFYJHUJI-UHFFFAOYSA-L 0.000 description 4
- 108010043135 L-methionine gamma-lyase Proteins 0.000 description 3
- 210000004027 cell Anatomy 0.000 description 3
- 238000004140 cleaning Methods 0.000 description 3
- 235000014113 dietary fatty acids Nutrition 0.000 description 3
- 239000000194 fatty acid Substances 0.000 description 3
- 229930195729 fatty acid Natural products 0.000 description 3
- 230000036541 health Effects 0.000 description 3
- 230000004060 metabolic process Effects 0.000 description 3
- 229960002920 sorbitol Drugs 0.000 description 3
- 230000019086 sulfide ion homeostasis Effects 0.000 description 3
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 2
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
- VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical compound [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 description 2
- CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 description 2
- 235000003363 Cornus mas Nutrition 0.000 description 2
- 240000006766 Cornus mas Species 0.000 description 2
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 2
- 208000032139 Halitosis Diseases 0.000 description 2
- SIKJAQJRHWYJAI-UHFFFAOYSA-N Indole Chemical compound C1=CC=C2NC=CC2=C1 SIKJAQJRHWYJAI-UHFFFAOYSA-N 0.000 description 2
- 229930195725 Mannitol Natural products 0.000 description 2
- MJVAVZPDRWSRRC-UHFFFAOYSA-N Menadione Chemical compound C1=CC=C2C(=O)C(C)=CC(=O)C2=C1 MJVAVZPDRWSRRC-UHFFFAOYSA-N 0.000 description 2
- ISWSIDIOOBJBQZ-UHFFFAOYSA-N Phenol Chemical compound OC1=CC=CC=C1 ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 description 2
- 102000019197 Superoxide Dismutase Human genes 0.000 description 2
- 108010012715 Superoxide dismutase Proteins 0.000 description 2
- 244000299461 Theobroma cacao Species 0.000 description 2
- 238000002835 absorbance Methods 0.000 description 2
- 230000037358 bacterial metabolism Effects 0.000 description 2
- 230000015572 biosynthetic process Effects 0.000 description 2
- 235000015895 biscuits Nutrition 0.000 description 2
- 235000019219 chocolate Nutrition 0.000 description 2
- 238000012258 culturing Methods 0.000 description 2
- 230000003247 decreasing effect Effects 0.000 description 2
- WQOXQRCZOLPYPM-UHFFFAOYSA-N dimethyl disulfide Chemical compound CSSC WQOXQRCZOLPYPM-UHFFFAOYSA-N 0.000 description 2
- 150000004665 fatty acids Chemical class 0.000 description 2
- 235000011187 glycerol Nutrition 0.000 description 2
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 2
- 239000000594 mannitol Substances 0.000 description 2
- 235000010355 mannitol Nutrition 0.000 description 2
- 230000007269 microbial metabolism Effects 0.000 description 2
- 229910017464 nitrogen compound Inorganic materials 0.000 description 2
- 150000002830 nitrogen compounds Chemical class 0.000 description 2
- IWDCLRJOBJJRNH-UHFFFAOYSA-N p-cresol Chemical compound CC1=CC=C(O)C=C1 IWDCLRJOBJJRNH-UHFFFAOYSA-N 0.000 description 2
- 208000028169 periodontal disease Diseases 0.000 description 2
- 239000008363 phosphate buffer Substances 0.000 description 2
- 239000002504 physiological saline solution Substances 0.000 description 2
- 239000013641 positive control Substances 0.000 description 2
- 230000001603 reducing effect Effects 0.000 description 2
- 239000000523 sample Substances 0.000 description 2
- ZFRKQXVRDFCRJG-UHFFFAOYSA-N skatole Chemical compound C1=CC=C2C(C)=CNC2=C1 ZFRKQXVRDFCRJG-UHFFFAOYSA-N 0.000 description 2
- 239000007921 spray Substances 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 239000000758 substrate Substances 0.000 description 2
- 229960004793 sucrose Drugs 0.000 description 2
- 235000000346 sugar Nutrition 0.000 description 2
- 238000003786 synthesis reaction Methods 0.000 description 2
- 229960001005 tuberculin Drugs 0.000 description 2
- 239000011592 zinc chloride Substances 0.000 description 2
- 235000005074 zinc chloride Nutrition 0.000 description 2
- BJEPYKJPYRNKOW-REOHCLBHSA-N (S)-malic acid Chemical compound OC(=O)[C@@H](O)CC(O)=O BJEPYKJPYRNKOW-REOHCLBHSA-N 0.000 description 1
- LDVVTQMJQSCDMK-UHFFFAOYSA-N 1,3-dihydroxypropan-2-yl formate Chemical compound OCC(CO)OC=O LDVVTQMJQSCDMK-UHFFFAOYSA-N 0.000 description 1
- SERLAGPUMNYUCK-DCUALPFSSA-N 1-O-alpha-D-glucopyranosyl-D-mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO[C@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O SERLAGPUMNYUCK-DCUALPFSSA-N 0.000 description 1
- XGRSAFKZAGGXJV-UHFFFAOYSA-N 3-azaniumyl-3-cyclohexylpropanoate Chemical compound OC(=O)CC(N)C1CCCCC1 XGRSAFKZAGGXJV-UHFFFAOYSA-N 0.000 description 1
- PVXPPJIGRGXGCY-DJHAAKORSA-N 6-O-alpha-D-glucopyranosyl-alpha-D-fructofuranose Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1OC[C@@H]1[C@@H](O)[C@H](O)[C@](O)(CO)O1 PVXPPJIGRGXGCY-DJHAAKORSA-N 0.000 description 1
- 244000215068 Acacia senegal Species 0.000 description 1
- 239000001736 Calcium glycerylphosphate Substances 0.000 description 1
- 229920002134 Carboxymethyl cellulose Polymers 0.000 description 1
- 206010007269 Carcinogenicity Diseases 0.000 description 1
- GHXZTYHSJHQHIJ-UHFFFAOYSA-N Chlorhexidine Chemical compound C=1C=C(Cl)C=CC=1NC(N)=NC(N)=NCCCCCCN=C(N)N=C(N)NC1=CC=C(Cl)C=C1 GHXZTYHSJHQHIJ-UHFFFAOYSA-N 0.000 description 1
- 102000008186 Collagen Human genes 0.000 description 1
- 108010035532 Collagen Proteins 0.000 description 1
- 102000020018 Cystathionine gamma-Lyase Human genes 0.000 description 1
- 108010045283 Cystathionine gamma-lyase Proteins 0.000 description 1
- ZZZCUOFIHGPKAK-UHFFFAOYSA-N D-erythro-ascorbic acid Natural products OCC1OC(=O)C(O)=C1O ZZZCUOFIHGPKAK-UHFFFAOYSA-N 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 241000233866 Fungi Species 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- 229920000084 Gum arabic Polymers 0.000 description 1
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- FFEARJCKVFRZRR-UHFFFAOYSA-N L-Methionine Natural products CSCCC(N)C(O)=O FFEARJCKVFRZRR-UHFFFAOYSA-N 0.000 description 1
- 239000004201 L-cysteine Substances 0.000 description 1
- 235000013878 L-cysteine Nutrition 0.000 description 1
- 229930195722 L-methionine Natural products 0.000 description 1
- 241000605894 Porphyromonas Species 0.000 description 1
- XUIMIQQOPSSXEZ-UHFFFAOYSA-N Silicon Chemical compound [Si] XUIMIQQOPSSXEZ-UHFFFAOYSA-N 0.000 description 1
- QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 1
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical compound [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 description 1
- 229930003268 Vitamin C Natural products 0.000 description 1
- VLSOAXRVHARBEQ-UHFFFAOYSA-N [4-fluoro-2-(hydroxymethyl)phenyl]methanol Chemical compound OCC1=CC=C(F)C=C1CO VLSOAXRVHARBEQ-UHFFFAOYSA-N 0.000 description 1
- 239000000205 acacia gum Substances 0.000 description 1
- 235000010489 acacia gum Nutrition 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- BJEPYKJPYRNKOW-UHFFFAOYSA-N alpha-hydroxysuccinic acid Natural products OC(=O)C(O)CC(O)=O BJEPYKJPYRNKOW-UHFFFAOYSA-N 0.000 description 1
- 229940024606 amino acid Drugs 0.000 description 1
- 235000001014 amino acid Nutrition 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 230000000675 anti-caries Effects 0.000 description 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 1
- 230000004888 barrier function Effects 0.000 description 1
- 210000002469 basement membrane Anatomy 0.000 description 1
- 235000021152 breakfast Nutrition 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- YYRMJZQKEFZXMX-UHFFFAOYSA-L calcium bis(dihydrogenphosphate) Chemical compound [Ca+2].OP(O)([O-])=O.OP(O)([O-])=O YYRMJZQKEFZXMX-UHFFFAOYSA-L 0.000 description 1
- 229910000019 calcium carbonate Inorganic materials 0.000 description 1
- 229940062672 calcium dihydrogen phosphate Drugs 0.000 description 1
- UHHRFSOMMCWGSO-UHFFFAOYSA-L calcium glycerophosphate Chemical compound [Ca+2].OCC(CO)OP([O-])([O-])=O UHHRFSOMMCWGSO-UHFFFAOYSA-L 0.000 description 1
- 229940095618 calcium glycerophosphate Drugs 0.000 description 1
- 235000019299 calcium glycerylphosphate Nutrition 0.000 description 1
- 229910000389 calcium phosphate Inorganic materials 0.000 description 1
- 229940041514 candida albicans extract Drugs 0.000 description 1
- 125000004432 carbon atom Chemical group C* 0.000 description 1
- 239000001569 carbon dioxide Substances 0.000 description 1
- 229910002092 carbon dioxide Inorganic materials 0.000 description 1
- 239000001768 carboxy methyl cellulose Substances 0.000 description 1
- 235000010948 carboxy methyl cellulose Nutrition 0.000 description 1
- 239000008112 carboxymethyl-cellulose Substances 0.000 description 1
- 230000007670 carcinogenicity Effects 0.000 description 1
- 231100000260 carcinogenicity Toxicity 0.000 description 1
- 239000006285 cell suspension Substances 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 229960003260 chlorhexidine Drugs 0.000 description 1
- 229920001436 collagen Polymers 0.000 description 1
- 238000004040 coloring Methods 0.000 description 1
- 230000000052 comparative effect Effects 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 238000001816 cooling Methods 0.000 description 1
- 229940112382 cysteine / methionine Drugs 0.000 description 1
- 239000008367 deionised water Substances 0.000 description 1
- 229910021641 deionized water Inorganic materials 0.000 description 1
- 208000002925 dental caries Diseases 0.000 description 1
- 239000000551 dentifrice Substances 0.000 description 1
- 239000002781 deodorant agent Substances 0.000 description 1
- 230000001877 deodorizing effect Effects 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 231100000676 disease causative agent Toxicity 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 210000002950 fibroblast Anatomy 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 210000003128 head Anatomy 0.000 description 1
- 235000013402 health food Nutrition 0.000 description 1
- 229940025294 hemin Drugs 0.000 description 1
- BTIJJDXEELBZFS-QDUVMHSLSA-K hemin Chemical compound CC1=C(CCC(O)=O)C(C=C2C(CCC(O)=O)=C(C)\C(N2[Fe](Cl)N23)=C\4)=N\C1=C/C2=C(C)C(C=C)=C3\C=C/1C(C)=C(C=C)C/4=N\1 BTIJJDXEELBZFS-QDUVMHSLSA-K 0.000 description 1
- 239000001257 hydrogen Substances 0.000 description 1
- 229910052739 hydrogen Inorganic materials 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- PZOUSPYUWWUPPK-UHFFFAOYSA-N indole Natural products CC1=CC=CC2=C1C=CN2 PZOUSPYUWWUPPK-UHFFFAOYSA-N 0.000 description 1
- RKJUIXBNRJVNHR-UHFFFAOYSA-N indolenine Natural products C1=CC=C2CC=NC2=C1 RKJUIXBNRJVNHR-UHFFFAOYSA-N 0.000 description 1
- 239000004310 lactic acid Substances 0.000 description 1
- 235000014655 lactic acid Nutrition 0.000 description 1
- 210000000265 leukocyte Anatomy 0.000 description 1
- 239000001630 malic acid Substances 0.000 description 1
- 235000011090 malic acid Nutrition 0.000 description 1
- 229960001855 mannitol Drugs 0.000 description 1
- 230000018984 mastication Effects 0.000 description 1
- 238000010077 mastication Methods 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 238000000034 method Methods 0.000 description 1
- 235000019691 monocalcium phosphate Nutrition 0.000 description 1
- 210000004400 mucous membrane Anatomy 0.000 description 1
- 229910052757 nitrogen Inorganic materials 0.000 description 1
- 235000015097 nutrients Nutrition 0.000 description 1
- 229920001542 oligosaccharide Polymers 0.000 description 1
- 150000002482 oligosaccharides Chemical class 0.000 description 1
- 235000015205 orange juice Nutrition 0.000 description 1
- 239000001301 oxygen Substances 0.000 description 1
- 229910052760 oxygen Inorganic materials 0.000 description 1
- 238000003359 percent control normalization Methods 0.000 description 1
- 230000035699 permeability Effects 0.000 description 1
- 229920000642 polymer Polymers 0.000 description 1
- 229920005862 polyol Polymers 0.000 description 1
- 150000003077 polyols Chemical class 0.000 description 1
- 239000008057 potassium phosphate buffer Substances 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- CVHZOJJKTDOEJC-UHFFFAOYSA-N saccharin Chemical compound C1=CC=C2C(=O)NS(=O)(=O)C2=C1 CVHZOJJKTDOEJC-UHFFFAOYSA-N 0.000 description 1
- 229940081974 saccharin Drugs 0.000 description 1
- 235000019204 saccharin Nutrition 0.000 description 1
- 239000000901 saccharin and its Na,K and Ca salt Substances 0.000 description 1
- 229910052710 silicon Inorganic materials 0.000 description 1
- 239000010703 silicon Substances 0.000 description 1
- 229940074386 skatole Drugs 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 229960004711 sodium monofluorophosphate Drugs 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 150000008163 sugars Chemical class 0.000 description 1
- 229910052717 sulfur Inorganic materials 0.000 description 1
- 239000011593 sulfur Substances 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 230000001629 suppression Effects 0.000 description 1
- 239000012085 test solution Substances 0.000 description 1
- 230000007704 transition Effects 0.000 description 1
- 241001148471 unidentified anaerobic bacterium Species 0.000 description 1
- 235000015112 vegetable and seed oil Nutrition 0.000 description 1
- 239000008158 vegetable oil Substances 0.000 description 1
- 235000019154 vitamin C Nutrition 0.000 description 1
- 239000011718 vitamin C Substances 0.000 description 1
- 235000012711 vitamin K3 Nutrition 0.000 description 1
- 239000011652 vitamin K3 Substances 0.000 description 1
- 229940041603 vitamin k 3 Drugs 0.000 description 1
- 239000012138 yeast extract Substances 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
- A61K31/047—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates having two or more hydroxy groups, e.g. sorbitol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/33—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing oxygen
- A61K8/34—Alcohols
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/60—Sugars; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q11/00—Preparations for care of the teeth, of the oral cavity or of dentures; Dentifrices, e.g. toothpastes; Mouth rinses
Definitions
- the present invention relates to a bad breath removing agent characterized by suppressing production of volatile sulfur compounds by sugar alcohol.
- VSC volatile sulfur compounds
- methyl mercaptan volatile nitrogen compounds
- dimethyl sulfide either alone or in combination.
- Other substances are detected in exhaled breath, but it is rare to detect concentrations above the human odor threshold.
- VSC the main cause of bad breath
- HSC hydrogen sulfide is produced from cysteine due to the involvement of bacterial cystathionine- ⁇ -syntase and cystathionine- ⁇ -lyase
- methyl mercaptan is produced from methionine due to the involvement of L-methionine- ⁇ -lyase.
- VSC is not only a malodorous substance but also has a strong biotoxicity. It has been reported that VSC enhances permeability of mucous membranes having a barrier function, promotes collagen synthesis inhibition of fibroblasts and damage of epithelial basement membrane, and inhibits synthesis. In particular, in experiments using human leukocytes, hydrogen sulfide increases the production of active oxygen, while strongly inhibiting superoxide dismutase (SOD), suggesting the possibility that VSC has carcinogenicity. Therefore, suppressing bad breath becomes important in maintaining oral health.
- SOD superoxide dismutase
- Patent Document 1 relates to the invention of chewing gum.
- a composition containing calcium dihydrogen phosphate and calcium glycerophosphate is kneaded with a gum base to produce a chewing gum, which is chewed, and has an immediate effect and sustainability of a bad breath effect.
- Panelists made a sensory evaluation.
- As a result in the case of 60% xylitol blended gum, 10/10 people recognized immediate effect and 7/10 people recognized durability.
- xylitol was replaced with 60% sucrose, 5/10 people recognized immediate effect and 3/10 people recognized sustainability.
- the effect of removing bad breath is improved by containing one or more sugar alcohols from the group consisting of xylitol, sorbitol, and erythritol in the chewing gum. It is described that 20 to 85% by weight, more preferably 30 to 80% by weight of the whole chewing gum is desirable.
- Patent Document 2 relates to a composition for oral cavity.
- an oral composition that prevents and suppresses bad breath, particularly bad breath caused by methioninase.
- Claim 1 describes that it contains one or more selected from the group consisting of mannitol, maltitol, sorbitol and a mixture thereof, and is usually 0.1% by mass or more in products and preparations. Preferably, it is blended at a ratio of 1 to 70% by mass.
- the sample solution containing 1% by mass of maltitol inhibits methionase activity by 20.0%. A report has been made.
- Patent Document 3 relates to a bad breath component cleaning composition and a composition for oral cavity containing the same, chewing gum and refreshing confectionery in the mouth.
- the present invention relates to a cleaning composition for cleaning odor components such as indole, skatole, phenol, p-cresol, and the composition for oral cavity.
- one or more kinds selected from sugar alcohols having 4 to 24 carbon atoms are included.
- sugar alcohols having 4 to 24 carbon atoms are included.
- sorbitol, xylitol, lactitol, maltitol, and palatinit are reported to be desirable.
- those containing erythritol and maltitol showed the most significant reduction in bad breath after 30 minutes of use for subjects with bad breath (sensory evaluation by three specialist panels).
- Patent Document 4 discloses a bad breath removal agent for phase transition, and in particular, a bad breath removal agent comprising a monoglyceride as a main base and comprising a polymer, a polyol, a bad breath removal active ingredient, and a solvent. From claim 14, it describes that non-fermentable sugar alcohol is included as a bad breath removing active ingredient, and from claim 16, as non-fermentable sugar alcohol, xylitol, sorbitol, erythritol, mannitol, maltitol, lactitol, paratinitol, palatinose. Describes oligosaccharides. Although patent document 4 is evaluating the bad breath removal effect by sensory evaluation using the comparative example and example which contain xylitol, the correlation between the xylitol content and the result of sensory evaluation is not confirmed.
- An object of the present invention is to provide a bad breath removing agent characterized by suppressing production of volatile sulfur compounds by sugar alcohol.
- VSC volatile nitrogen compounds
- lower fatty acids etc.
- VSC has been reported to show a strong correlation between the odor intensity of the sensory test and the concentration detected from the oral cavity.
- erythritol, lactitol, and maltitol suppressed the generation of hydrogen sulfide and methyl mercaptan in a pH-independent manner.
- lactitol and maltitol reduce hydrogen sulfide production to about 40-60% at a concentration of 10% against P. gingivalis, the main causative agent of periodontal disease.
- the present invention exhibits a remarkable volatile sulfur compound production inhibitory action, it can be used as a preparation such as a mouthwash, a toothpaste, an inhalant, a troche, and chewing gum, candy, tablet confectionery, gummy jelly, It can be used and ingested daily as a food such as biscuits and chocolates, sorbets and beverages, and is effective in improving and preventing bad breath.
- One embodiment of the present invention is a bad breath remover containing sugar alcohol as an active ingredient.
- a further embodiment of the present invention is the bad breath remover as described above, wherein the sugar alcohol is lactitol.
- Another embodiment of the present invention is a mouthwash, a toothpaste, an inhalant, and a troche comprising a bad breath remover containing sugar alcohol as an active ingredient.
- Still another embodiment of the present invention is a food comprising a bad breath remover containing sugar alcohol as an active ingredient.
- Still another embodiment of the present invention is a food such as chewing gum, candy, tablet confectionery, gummy jelly, biscuits, chocolate and other confectionery, sorbet, beverage and the like containing a bad breath remover containing sugar alcohol as an active ingredient. is there.
- Another embodiment of the present invention is a production inhibitor of volatile sulfur compounds by inhibiting methionine and cysteine metabolic pathways containing sugar alcohol as an active ingredient.
- Still another embodiment of the present invention is the volatile sulfur compound production inhibitor as described above, wherein the sugar alcohol is lactitol or maltitol.
- Example 1 Sugar alcohol saliva incubation test was performed as follows.
- Sample preparation As samples, xylitol, erythritol, lactitol, maltitol, and sucrose were used. Each was dissolved in deionized water to an appropriate concentration to obtain a sample solution.
- Saliva Incubation Test Four healthy adults (A, B, C, D, average age 32.0 years) were subjects, and the test was conducted in duplicate. Between 9:00 am and 9:30 am, 10 ml of unstimulated saliva was collected from each subject (no breakfast or toothpaste on the day of collection). The collected saliva was stored on ice. 0.5 ml of the sample solution was added to 1.0 ml of unstimulated saliva and cultured at 37 ° C. for 23 hours. After incubation for 23 hours, the samples were placed on ice. Before GC analysis, the sample was shaken at 37 ° C. for 15 minutes, an appropriate amount of headspace gas was taken with a syringe, and GC analysis was performed. In the test under neutral conditions, potassium phosphate buffer was added to a final concentration of 20 mM, and the reaction solution was maintained in a neutral region.
- GC analysis For GC analysis, GC6890 manufactured by Agilent was used. HP-PLOTQ (30m ⁇ 0.53mm ⁇ 40 ⁇ m) is used as the analytical column, initial temperature: 70 ° C / 2.5min, temperature rise: 30 ° C / min, final temperature: 190 ° C / 3.5min, inlet temperature: 200 ° C, Analysis was performed under the conditions of detector: FPD, detector temperature: 200 ° C., flow rate: 20 ml / min. Regarding RT, hydrogen sulfide is 1.1 min, methyl mercaptan is 4.0 min, dimethyl monosulfide is 5.6 min, and dimethyl disulfide is 8.3 min. All samples were performed in duplicate and calculated as an average value.
- sucrose inhibitory effect of sucrose is pH dependent.
- the increase in the amount of VSC generated by adding sucrose under neutral conditions is thought to be due to the fact that sucrose becomes a nutrient source for oral bacteria and the number of bacteria that cause bad breath is increased.
- sucrose becomes a nutrient source for oral bacteria
- the number of bacteria that cause bad breath is increased.
- bacteria in the oral cavity increase due to sucrose, but as sucrose is assimilated, lactic acid and the like are discharged, pH is lowered, and methioninase activity and cysteine metabolizing enzyme activity are inhibited.
- methioninase activity and cysteine metabolizing enzyme activity are inhibited.
- it is thought that the occurrence of VSC is suppressed because the growth of bad breath causing bacteria is suppressed.
- FIG. 2 shows the results of the saliva incubation test described above with xylitol at final concentrations of 1.43% and 5.7%. In this test using xylitol, there was no significant change in the generation amount of hydrogen sulfide / methyl mercaptan and the pH of the reaction solution in all panelists.
- Example 2 Bacterial metabolism inhibition test of sugar alcohols was performed as follows.
- F. nucleatum was anaerobically cultured in 3% THB medium containing 0.05% L-cysteine hydrochloride for 1 day. After culturing for 1 day, it was confirmed that the absorbance at 550 nm was 0.8 or more, and the supernatant was discarded after centrifugation at 5000 rpm for 4 minutes. Suspend the bacterial cells in physiological saline and repeat the same procedure. Suspend the bacterial cells in physiological saline twice the amount of the original bacterial solution, and use it for ice cooling. .
- P. gingivalis was anaerobically cultured in TSB medium (3% TripticaseticSoy Broth, 0.3% Yeast Extract, 0.0005% hemin, 0.00005% menadione) for 1 day. After culturing for 1 day, it was confirmed that the absorbance at 550 nm was 1.4 or more, and a bacterial solution was prepared in the same manner as described above.
- TSB medium 3% TripticaseticSoy Broth, 0.3% Yeast Extract, 0.0005% hemin, 0.00005% menadione
- Cysteine metabolic pathway inhibition test A cysteine metabolic pathway inhibition test was conducted in the same manner as the methionine metabolic pathway inhibition test, except that L-cysteine was used as a substrate.
- gingivalis cysteine metabolic pathway lactitol, maltitol, and sucrose reduced hydrogen sulfide production to about 40-60% at a final concentration of 10%.
- no clear effect was observed for xylitol and erythritol.
- a mouthwash, a toothpaste, a mouth spray, a troche, a chewing gum, a candy, a tablet candy, a gummy jelly, and a beverage containing the halitosis remover of the present invention were produced by conventional methods. Their formulations are shown below. Note that the scope of the present invention is not limited by these.
- Example 3 A mouthwash was prepared according to the following formulation. Ethanol 2.0% by weight Lactitol 10.0 Fragrance 1.0 Water remaining 100.0
- Example 4 A toothpaste was produced according to the following formulation. Calcium carbonate 40.0% by weight Glycerin 10.0 Maltitol 20.0 Carboxymethylcellulose 2.0 Sodium ralyl sulfate 2.0 Fragrance 1.0 Saccharin 0.1 Chlorhexidine 0.01 Water remaining 100.0
- Example 5 A mouse spray was produced according to the following formulation. Ethanol 10.0% by weight Glycerin 5.0 Lactitol 10.0 Maltitol 10.0 Fragrance 0.05 Coloring 0.001 Water remaining 100.0
- Example 6 A lozenge was produced according to the following formulation. Maltitol 72.3 wt% Xylitol 20.0 Gum arabic 6.0 Fragrance 1.0 Sodium monofluorophosphate 0.7 100.0
- Chewing gum was manufactured according to the following formulation. Gum base 20.0% by weight Maltitol 45.0 Lactitol 33.0 Fragrance 2.0 100.0
- Example 8 Candy was manufactured according to the following prescription. Maltitol 50.0% by weight Reduced water candy 34.0 Citric acid 2.0 Fragrance 0.2 Water remaining 100.0
- Example 9 Tablet confectionery was produced according to the following prescription. Maltitol 76.1% by weight Lactitol 19.0 Sucrose fatty acid ester 0.2 Fragrance 0.2 Water 4.5 100.0
- Example 10 Gummy jelly was manufactured according to the following prescription. Gelatin 60.0% by weight Reduced water candy 21.40 Maltitol 11.5 Vegetable oil 4.5 Malic acid 2.0 Fragrance 0.5 100.0
- Example 11 A beverage was produced according to the following formulation. Orange juice 30.0% by weight Lactitol 15.0 Citric acid 0.1 Vitamin C 0.04 Fragrance 0.1 Water remaining 100.0
- the bad breath remover containing the sugar alcohol of the present invention can be applied to gums, candy, tablet confectionery, etc., and can also be applied to bad breath removal specific health foods.
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical & Material Sciences (AREA)
- Epidemiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Birds (AREA)
- Communicable Diseases (AREA)
- Oral & Maxillofacial Surgery (AREA)
- Oncology (AREA)
- Emergency Medicine (AREA)
- Cosmetics (AREA)
- Confectionery (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Coloring Foods And Improving Nutritive Qualities (AREA)
- Medicinal Preparation (AREA)
Abstract
Description
糖アルコール類の唾液インキュベート試験を以下のように行った。 Example 1
Sugar alcohol saliva incubation test was performed as follows.
試料としては、キシリトール、エリスリトール、ラクチトール、マルチトール、スクロースを用いた。それぞれ、適当な濃度になるよう脱イオン水に溶解し、試料溶液とした。 1-1. Sample preparation As samples, xylitol, erythritol, lactitol, maltitol, and sucrose were used. Each was dissolved in deionized water to an appropriate concentration to obtain a sample solution.
健常な成人4名(A,B,C,D,平均年齢32.0才)を被験者とし、試験は二連で実施した。朝9:00~9:30の間に、各被験者から無刺激唾液を10ml採取した(採取する日は、朝食を取らず、歯磨きをしない)。採取した唾液は氷上で保存した。無刺激唾液1.0mlに試料溶液0.5mlを加え、37℃で23時間培養した。23時間培養後、サンプルを氷上に置いた。GC分析前にサンプルを37℃で15分間振とうし、ヘッドスペースガスをシリンジにより適当量とり、GC分析を行った。尚、中性条件下での試験は、リン酸カリウムバッファーを最終濃度20mMになるよう加え、反応液を中性領域に維持した。 1-2. Saliva Incubation Test Four healthy adults (A, B, C, D, average age 32.0 years) were subjects, and the test was conducted in duplicate. Between 9:00 am and 9:30 am, 10 ml of unstimulated saliva was collected from each subject (no breakfast or toothpaste on the day of collection). The collected saliva was stored on ice. 0.5 ml of the sample solution was added to 1.0 ml of unstimulated saliva and cultured at 37 ° C. for 23 hours. After incubation for 23 hours, the samples were placed on ice. Before GC analysis, the sample was shaken at 37 ° C. for 15 minutes, an appropriate amount of headspace gas was taken with a syringe, and GC analysis was performed. In the test under neutral conditions, potassium phosphate buffer was added to a final concentration of 20 mM, and the reaction solution was maintained in a neutral region.
GC分析に関しては、すべてAgilent社製のGC6890を用いた。分析カラムはHP-PLOTQ(30m×0.53mm×40μm)を用い、初期温度:70℃/2.5min、昇温:30℃/min、終温度:190℃/3.5min、注入口温度:200℃、検出器:FPD、検出器温度:200℃、流量:20ml/minの条件で分析した。RTに関しては、硫化水素が1.1min、メチルメルカプタンが4.0min、ジメチルモノスルフィドが5.6min、ジメチルジスルフィドが8.3minである。全てのサンプルは二連で行い、平均値として算出した。 1-3. GC analysis For GC analysis, GC6890 manufactured by Agilent was used. HP-PLOTQ (30m × 0.53mm × 40μm) is used as the analytical column, initial temperature: 70 ° C / 2.5min, temperature rise: 30 ° C / min, final temperature: 190 ° C / 3.5min, inlet temperature: 200 ° C, Analysis was performed under the conditions of detector: FPD, detector temperature: 200 ° C., flow rate: 20 ml / min. Regarding RT, hydrogen sulfide is 1.1 min, methyl mercaptan is 4.0 min, dimethyl monosulfide is 5.6 min, and dimethyl disulfide is 8.3 min. All samples were performed in duplicate and calculated as an average value.
1. スクロースの効果
上記唾液インキュベート試験において、スクロースを最終濃度0.057、0.114%になるように添加した。その結果、最終濃度が0.057%のときは、pHに変化はなく、VSCの発生にもほとんど変化がなかったが、最終濃度が0.114%のときに、pHが5.6と酸性に傾き、硫化水素・メチルメルカプタンの発生も抑制された。これらの結果を図1に示す。 1-4.
キシリトールに関して、最終濃度1.43%、5.7%の濃度で上記した唾液インキュベート試験を行った結果を図2に示す。キシリトールを使用した本試験では全パネラーにおいて、硫化水素・メチルメルカプタンの発生量、および反応液のpHに大きな変化はなかった。 2. Effect of Xylitol FIG. 2 shows the results of the saliva incubation test described above with xylitol at final concentrations of 1.43% and 5.7%. In this test using xylitol, there was no significant change in the generation amount of hydrogen sulfide / methyl mercaptan and the pH of the reaction solution in all panelists.
エリスリトールに関しては、図3に示すように、エリスリトールを添加しても、反応液のpHは変化しないが、硫化水素・メチルメルカプタンの発生量は添加濃度依存的に抑制された。 3. Effect of Erythritol As shown in FIG. 3, even when erythritol was added, the pH of the reaction solution did not change, but the amount of hydrogen sulfide / methyl mercaptan generated was suppressed depending on the addition concentration.
ラクチトールに関しては、図4-1に示すように、ラクチトールの添加により、反応液のpHが変わらない人(2/4名)とpHが低下する人(2/4名)がいた。どちらのパネラーにおいても、硫化水素・メチルメルカプタンの発生量は抑制された。 4). Effect of Lactitol As shown in FIG. 4-1, there was a person (2/4) who did not change the pH of the reaction solution and a person (2/4) whose pH decreased due to the addition of lactitol. In both panelists, the generation of hydrogen sulfide and methyl mercaptan was suppressed.
マルチトールに関しては、マルチトールの添加により、反応液のpHが変わらない人(1/4名)とpHが低下する人(3/4名)がいた。図5-1に示すように、全パネラーにおいて、マルチトールを添加しても硫化水素の発生量にほとんど変化は見られなかった。一方、メチルメルカプタンの発生はマルチトールの添加により抑制された。中性条件下では、図5-2に示すように、硫化水素の発生量は上昇する傾向にあったが、メチルメルカプタンの発生は抑制された。 5. The effect of maltitol
Regarding maltitol, there were some people (1/4 people) who did not change the pH of the reaction solution due to the addition of maltitol and others (3/4 people) whose pH decreased. As shown in FIG. 5-1, in all the panelists, even when maltitol was added, the amount of hydrogen sulfide generated hardly changed. On the other hand, the generation of methyl mercaptan was suppressed by the addition of maltitol. Under neutral conditions, as shown in FIG. 5-2, the generation amount of hydrogen sulfide tended to increase, but the generation of methyl mercaptan was suppressed.
糖アルコール類の菌代謝阻害試験を以下のように行った。 (Example 2)
Bacterial metabolism inhibition test of sugar alcohols was performed as follows.
菌株としては、F.nucleatumとP.gingivalisを用いた。 2-1. Preparation of fungus F. nucleatum and P. gingivalis were used as strains.
試験管に0.1Mリン酸緩衝液(pH6.5)2.47mlと被験液0.03mlを入れた。ヘッドスペースを混合ガス(窒素:水素:炭酸ガス=8:1:1)で置換後、シリコン栓で密封、攪拌し、37℃の水浴に保温した。5分経過後菌液0.2mlを、ツベルクリン注射器を用いて注入し、攪拌し保温した。5分後にL-メチオニン溶液(0.5%)0.3mlを、ツベルクリン注射器を用いて注入、攪拌し、10分間37℃で保温した。ヘッドスペースガス500μlを抜き取りGC分析でメチルメルカプタン量を測定した。GC分析条件は上記1-3と同様に行った。 2-2. Methionine metabolic pathway inhibition test 2.47 ml of 0.1 M phosphate buffer (pH 6.5) and 0.03 ml of the test solution were placed in a test tube. The head space was replaced with a mixed gas (nitrogen: hydrogen: carbon dioxide gas = 8: 1: 1), sealed with a silicon stopper, stirred, and kept in a 37 ° C. water bath. After 5 minutes, 0.2 ml of the bacterial solution was injected using a tuberculin syringe, stirred and kept warm. After 5 minutes, 0.3 ml of L-methionine solution (0.5%) was injected using a tuberculin syringe, stirred, and kept at 37 ° C. for 10 minutes. A 500 μl headspace gas was withdrawn and the amount of methyl mercaptan was measured by GC analysis. The GC analysis conditions were the same as in 1-3 above.
基質としてL-システインを使用した以外は、上記メチオニン代謝経路阻害試験と同様な方法でシステイン代謝経路阻害試験を行った。 2-3. Cysteine metabolic pathway inhibition test A cysteine metabolic pathway inhibition test was conducted in the same manner as the methionine metabolic pathway inhibition test, except that L-cysteine was used as a substrate.
1. メチオニン代謝経路阻害試験
Fusobacterium nucleatum(以下、F.nucleatumと略す)およびPorphyromonas gingivalis(以下、P.gingivalisと略す)メチオニン代謝経路に対する、糖アルコールおよびスクロースの阻害活性を確認した結果を図6-1の(a)、(b)に示す。F.nucleatumメチオニン代謝経路に対しては、ポジティブコントロールである塩化亜鉛はfinal 100ppmでメチルメルカプタンの発生量を40%(コントロールを100%として)まで減少させた。一方、どの糖アルコールも、final 10%の濃度ではメチルメルカプタンの発生量を80%程度まで抑制し、非常に弱いながらメチオニン代謝阻害活性が認められた。また、P.gingivalisのメチオニン代謝経路に対しては、ポジティブコントロールの塩化亜鉛がメチルメルカプタンの発生量を23%まで抑制した。また、ラクチトール、マルチトールは弱いながらもメチルメルカプタンの発生量を80~90%程度まで抑制したが、キシリトール、エリスリトールについては明確な阻害効果が認められなかった。 2-4.
F.nucleatumおよびP.gingivalisシステイン代謝経路に対する、糖アルコールおよびスクロースの阻害活性を確認した結果を図6-2の(c)、(d)に示す。F.nucleatumシステイン代謝経路に対しては、キシリトール、エリスリトール、ラクチトール、マルチトールはfinal 10%の濃度で硫化水素の産生量を約60~80%近くまで減少させた。スクロースに関しては、硫化水素の発生量を約40%まで抑制した。また、P.gingivalisシステイン代謝経路に対しては、ラクチトール、マルチトール、スクロースがfinal 10%の濃度で硫化水素の産生量を約40~60%まで減少させた。一方、キシリトール、エリスリトールに関しては、明瞭な効果は認められなかった。 2. Cysteine Metabolic Pathway Inhibition Test The results of confirming the inhibitory activity of sugar alcohol and sucrose on the F.nucleatum and P.gingivalis cysteine metabolic pathways are shown in FIGS. 6-2 (c) and (d). For the F. nucleatum cysteine metabolic pathway, xylitol, erythritol, lactitol, and maltitol reduced hydrogen sulfide production to about 60-80% at a final 10% concentration. Regarding sucrose, the amount of hydrogen sulfide generated was suppressed to about 40%. For P. gingivalis cysteine metabolic pathway, lactitol, maltitol, and sucrose reduced hydrogen sulfide production to about 40-60% at a final concentration of 10%. On the other hand, no clear effect was observed for xylitol and erythritol.
下記処方に従って含そう剤を製造した。
エタノール 2.0重量%
ラクチトール 10.0
香料 1.0
水 残
100.0 (Example 3)
A mouthwash was prepared according to the following formulation.
Ethanol 2.0% by weight
Lactitol 10.0
Fragrance 1.0
Water remaining
100.0
下記処方に従って練り歯磨きを製造した。
炭酸カルシウム 40.0重量%
グリセリン 10.0
マルチトール 20.0
カルボオキシメチルセルロース 2.0
ラルリル硫酸ナトリウム 2.0
香料 1.0
サッカリン 0.1
クロルヘキシジン 0.01
水 残
100.0 Example 4
A toothpaste was produced according to the following formulation.
Calcium carbonate 40.0% by weight
Glycerin 10.0
Maltitol 20.0
Carboxymethylcellulose 2.0
Sodium ralyl sulfate 2.0
Fragrance 1.0
Saccharin 0.1
Chlorhexidine 0.01
Water remaining
100.0
下記処方に従ってマウススプレーを製造した。
エタノール 10.0重量%
グリセリン 5.0
ラクチトール 10.0
マルチトール 10.0
香料 0.05
着色料 0.001
水 残
100.0 (Example 5)
A mouse spray was produced according to the following formulation.
Ethanol 10.0% by weight
Glycerin 5.0
Lactitol 10.0
Maltitol 10.0
Fragrance 0.05
Coloring 0.001
Water remaining
100.0
下記処方に従ってトローチを製造した。
マルチトール 72.3重量%
キシリトール 20.0
アラビアガム 6.0
香料 1.0
モノフルオロリン酸ナトリウム 0.7
100.0 (Example 6)
A lozenge was produced according to the following formulation.
Maltitol 72.3 wt%
Xylitol 20.0
Gum arabic 6.0
Fragrance 1.0
Sodium monofluorophosphate 0.7
100.0
下記処方に従ってチューインガムを製造した。
ガムベース 20.0重量%
マルチトール 45.0
ラクチトール 33.0
香料 2.0
100.0 (Example 7)
Chewing gum was manufactured according to the following formulation.
Gum base 20.0% by weight
Maltitol 45.0
Lactitol 33.0
Fragrance 2.0
100.0
下記処方に従ってキャンディを製造した。
マルチトール 50.0重量%
還元水あめ 34.0
クエン酸 2.0
香料 0.2
水 残
100.0 (Example 8)
Candy was manufactured according to the following prescription.
Maltitol 50.0% by weight
Reduced water candy 34.0
Citric acid 2.0
Fragrance 0.2
Water remaining
100.0
下記処方に従って錠菓を製造した。
マルチトール 76.1重量%
ラクチトール 19.0
ショ糖脂肪酸エステル 0.2
香料 0.2
水 4.5
100.0 Example 9
Tablet confectionery was produced according to the following prescription.
Maltitol 76.1% by weight
Lactitol 19.0
Sucrose fatty acid ester 0.2
Fragrance 0.2
Water 4.5
100.0
下記処方に従ってグミゼリーを製造した。
ゼラチン 60.0重量%
還元水あめ 21.40
マルチトール 11.5
植物油脂 4.5
リンゴ酸 2.0
香料 0.5
100.0 (Example 10)
Gummy jelly was manufactured according to the following prescription.
Gelatin 60.0% by weight
Reduced water candy 21.40
Maltitol 11.5
Vegetable oil 4.5
Malic acid 2.0
Fragrance 0.5
100.0
下記処方に従って飲料を製造した。
オレンジ果汁 30.0重量%
ラクチトール 15.0
クエン酸 0.1
ビタミンC 0.04
香料 0.1
水 残
100.0 (Example 11)
A beverage was produced according to the following formulation.
Orange juice 30.0% by weight
Lactitol 15.0
Citric acid 0.1
Vitamin C 0.04
Fragrance 0.1
Water remaining
100.0
This application claims priority from Japanese Patent Application No. 2009-165556 filed on Jul. 14, 2009, the contents of which are incorporated herein by reference.
Claims (11)
- 糖アルコールを有効成分とする口臭除去剤 Bad breath remover containing sugar alcohol as an active ingredient
- 前記糖アルコールが、ラクチトールである請求項1に記載の口臭除去剤。 The bad breath removing agent according to claim 1, wherein the sugar alcohol is lactitol.
- 糖アルコールを有効成分とする口臭除去剤からなる、含そう剤、練り歯磨き剤、吸入剤、トローチ剤。 An oral repellent, toothpaste, inhalant, and lozenge consisting of a bad breath remover containing sugar alcohol as an active ingredient.
- 前記糖アルコールが、ラクチトールである請求項3に記載の含そう剤、練り歯磨き剤、吸入剤、トローチ剤。 The mouthwash, toothpaste, inhalant, and lozenge according to claim 3, wherein the sugar alcohol is lactitol.
- 糖アルコールを有効成分とする口臭除去剤からなる食品。 Food made of bad breath remover containing sugar alcohol as an active ingredient.
- 前記糖アルコールが、ラクチトールである請求項5に記載の食品。 The food according to claim 5, wherein the sugar alcohol is lactitol.
- 糖アルコールを有効成分とするメチオニンおよびシステイン代謝経路阻害による揮発性硫黄化合物の産生抑制剤。 A volatile sulfur compound production inhibitor that inhibits methionine and cysteine metabolic pathways with sugar alcohol as an active ingredient.
- 前記糖アルコールが、ラクチトール、マルチトールである請求項7に記載の揮発性硫黄化合物の産生抑制剤。 The volatile sulfur compound production inhibitor according to claim 7, wherein the sugar alcohol is lactitol or maltitol.
- 糖アルコールを有効成分とするメチオニンおよびシステイン代謝経路阻害による揮発性硫黄化合物の産生抑制剤からなる、含そう剤、練り歯磨き剤、吸入剤、トローチ剤。 A mouthwash, a toothpaste, an inhalant, and a lozenge comprising a methionine and cysteine metabolic pathway inhibitor that inhibits sugar alcohol as an active ingredient.
- 前記糖アルコールが、ラクチトール、マルチトールである請求項9に記載の含そう剤、練り歯磨き剤、吸入剤、トローチ剤。 10. The mouthwash, toothpaste, inhalant, and lozenge according to claim 9, wherein the sugar alcohol is lactitol or maltitol.
- 糖アルコールを有効成分とするメチオニンおよびシステイン代謝経路阻害による揮発性硫黄化合物の産生抑制剤からなる食品。
A food comprising an inhibitor of production of volatile sulfur compounds by inhibiting methionine and cysteine metabolic pathways containing sugar alcohol as an active ingredient.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN2010800297111A CN102470114A (en) | 2009-07-14 | 2010-07-13 | Bad breath-removing agent |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2009165556A JP2011020936A (en) | 2009-07-14 | 2009-07-14 | Foul breath remover |
JP2009-165556 | 2009-07-14 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2011007552A1 true WO2011007552A1 (en) | 2011-01-20 |
Family
ID=43449162
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/JP2010/004531 WO2011007552A1 (en) | 2009-07-14 | 2010-07-13 | Bad breath-removing agent |
Country Status (5)
Country | Link |
---|---|
JP (1) | JP2011020936A (en) |
KR (1) | KR20120042969A (en) |
CN (2) | CN102470114A (en) |
TW (1) | TW201116272A (en) |
WO (1) | WO2011007552A1 (en) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2019135951A (en) * | 2018-02-08 | 2019-08-22 | 株式会社マンダム | Screening method of halitosis inhibiting component |
Families Citing this family (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP6371336B2 (en) * | 2015-06-17 | 2018-08-08 | 花王株式会社 | Odor suppressor for polysulfide compounds |
EP3711040A1 (en) * | 2017-11-16 | 2020-09-23 | The Procter and Gamble Company | Product demonstration device and method thereof |
Citations (12)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPH048251A (en) * | 1990-04-26 | 1992-01-13 | Mitsui Sugar Co Ltd | Chewing gum containing sweetnees-keeping coating sugars and its preparation |
JPH09252723A (en) * | 1996-01-18 | 1997-09-30 | Lotte Co Ltd | New milk and milk powder freed of lactose, food and drink containing the same and production of milk and milk powder freed of lactose |
US6071500A (en) * | 1999-01-19 | 2000-06-06 | Thistle; Robert H. | Breath spray with tooth decay and halitosis prevention characteristics |
US20020132000A1 (en) * | 2001-01-12 | 2002-09-19 | Marie-Helene Saniez | Sweet with a rough texture intended for the treatment of halitosis |
JP2003160458A (en) * | 2001-11-22 | 2003-06-03 | Kansai Koso Kk | Composition for oral cavity |
WO2003090704A1 (en) * | 2002-04-23 | 2003-11-06 | Ezaki Glico Co., Ltd. | Foods having effect of eliminating bad breath |
JP2004203872A (en) * | 2002-12-12 | 2004-07-22 | Kao Corp | Bad breath component cleaning composition, oral composition containing the same, chewing gum and refreshing confectionery in mouth |
JP2006325455A (en) * | 2005-05-25 | 2006-12-07 | Kao Corp | Chewing gum |
JP2007185191A (en) * | 2006-01-13 | 2007-07-26 | Lotte Confectionery Co Ltd | Translucent shell-like confectionery composition |
JP2008142077A (en) * | 2006-12-11 | 2008-06-26 | Lotte Confectionery Co Ltd | Method for producing confectionery topped with flake nuts |
JP2009500399A (en) * | 2005-07-08 | 2009-01-08 | エル・ジー ハウスホールド アンド ヘルスケア リミティッド | Bad breath removal agent for phase transition |
JP2009286749A (en) * | 2008-05-30 | 2009-12-10 | Kanro Kk | Solid material for oral cavity hygiene |
Family Cites Families (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1146863A (en) * | 1994-06-08 | 1997-04-09 | 王昌志 | Method for producing sweetmeat for refreshing mouth |
TW200804345A (en) * | 2005-08-30 | 2008-01-16 | Novartis Ag | Substituted benzimidazoles and methods of preparation |
CN101124992A (en) * | 2007-09-07 | 2008-02-20 | 王建林 | 'Jinsuoyinkai' health-care sugar and production technology thereof |
-
2009
- 2009-07-14 JP JP2009165556A patent/JP2011020936A/en active Pending
-
2010
- 2010-07-13 CN CN2010800297111A patent/CN102470114A/en active Pending
- 2010-07-13 KR KR1020127003727A patent/KR20120042969A/en not_active Withdrawn
- 2010-07-13 CN CN201310746158.9A patent/CN103690385A/en active Pending
- 2010-07-13 WO PCT/JP2010/004531 patent/WO2011007552A1/en active Application Filing
- 2010-07-14 TW TW099123130A patent/TW201116272A/en unknown
Patent Citations (12)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPH048251A (en) * | 1990-04-26 | 1992-01-13 | Mitsui Sugar Co Ltd | Chewing gum containing sweetnees-keeping coating sugars and its preparation |
JPH09252723A (en) * | 1996-01-18 | 1997-09-30 | Lotte Co Ltd | New milk and milk powder freed of lactose, food and drink containing the same and production of milk and milk powder freed of lactose |
US6071500A (en) * | 1999-01-19 | 2000-06-06 | Thistle; Robert H. | Breath spray with tooth decay and halitosis prevention characteristics |
US20020132000A1 (en) * | 2001-01-12 | 2002-09-19 | Marie-Helene Saniez | Sweet with a rough texture intended for the treatment of halitosis |
JP2003160458A (en) * | 2001-11-22 | 2003-06-03 | Kansai Koso Kk | Composition for oral cavity |
WO2003090704A1 (en) * | 2002-04-23 | 2003-11-06 | Ezaki Glico Co., Ltd. | Foods having effect of eliminating bad breath |
JP2004203872A (en) * | 2002-12-12 | 2004-07-22 | Kao Corp | Bad breath component cleaning composition, oral composition containing the same, chewing gum and refreshing confectionery in mouth |
JP2006325455A (en) * | 2005-05-25 | 2006-12-07 | Kao Corp | Chewing gum |
JP2009500399A (en) * | 2005-07-08 | 2009-01-08 | エル・ジー ハウスホールド アンド ヘルスケア リミティッド | Bad breath removal agent for phase transition |
JP2007185191A (en) * | 2006-01-13 | 2007-07-26 | Lotte Confectionery Co Ltd | Translucent shell-like confectionery composition |
JP2008142077A (en) * | 2006-12-11 | 2008-06-26 | Lotte Confectionery Co Ltd | Method for producing confectionery topped with flake nuts |
JP2009286749A (en) * | 2008-05-30 | 2009-12-10 | Kanro Kk | Solid material for oral cavity hygiene |
Non-Patent Citations (2)
Title |
---|
EI HASHINO ET AL.: "Erythritol wa Shishubyogensei Saikin no Kihatsusei Ryukabutsu Sansei o Yokusei suru", JOURNAL OF DENTAL HEALTH, vol. 59, no. 5, 30 October 2009 (2009-10-30), pages 608 - 609 + P12 * |
YUJI KODAMA ET AL.: "Kihatsusei Io Kagobutsu no Sansei ni Oyobosu To Alcohol no Eikyo", THE 56TH PROCEEDINGS OF JAPANESE SOCIETY OF FOOD SCIENCE AND TECHNOLOGY, 10 September 2009 (2009-09-10), pages 137 + 3FP11 * |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2019135951A (en) * | 2018-02-08 | 2019-08-22 | 株式会社マンダム | Screening method of halitosis inhibiting component |
JP6989742B2 (en) | 2018-02-08 | 2022-01-12 | 株式会社マンダム | Screening method for halitosis-suppressing ingredients |
Also Published As
Publication number | Publication date |
---|---|
KR20120042969A (en) | 2012-05-03 |
JP2011020936A (en) | 2011-02-03 |
CN102470114A (en) | 2012-05-23 |
CN103690385A (en) | 2014-04-02 |
TW201116272A (en) | 2011-05-16 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
RU2125440C1 (en) | Nonalcoholic antibacterial composition for mouth rinsing (variants), method of suppression of mouth cavity microorganisms (variants) and a method of elimination of mouth unpleasant odor (variants) | |
US20090252690A1 (en) | Flavoured Mouth Wash Composition | |
RU2504368C2 (en) | SOLID CHEWING COMPOSITION AND METHOD OF INHIBITING Streptococcus mutans DEVELOPMENT | |
US20090269288A1 (en) | Black pearl toothpaste | |
EP3164107A2 (en) | Lactone-containing compositions for malodor elimination | |
JPH07316064A (en) | Suppressor for causative of periodontal disease or caries and composition for oral cavity and food containing the same | |
CN103717225A (en) | Compositions containing zinc salts and isothiocyanates for reduction of oral volatile sulfur compounds (vscs) | |
WO2011007552A1 (en) | Bad breath-removing agent | |
KR102288921B1 (en) | Composition for prevention or treatment or oral disease | |
Wessel et al. | Magnolia bark extract increases oral bacterial cell surface hydrophobicity and improves self-perceived breath freshness when added to chewing gum | |
KR100450391B1 (en) | Toothpaste Composition | |
KR19980013946A (en) | Oral composition of liquid type | |
JP6249438B2 (en) | Oral hygiene improving active composition | |
JP2011236144A (en) | Composition for oral cavity, and foul-breath inhibitor | |
KR101660467B1 (en) | Oral composition containing fermentative extract of lycii fructus as active ingredient | |
KR20190094987A (en) | Composition for prevention or treatment of oral disease comprising Ginkgo biloba extract | |
JP2015000056A (en) | Confectionery | |
WO2014074753A1 (en) | Oral care composition containing theaflavin extract | |
KR102459936B1 (en) | Composition for prevention or treatment of oral disease comprising Alkannin | |
JP2014094968A (en) | Foul breath remover | |
WO2023222213A1 (en) | Antimicrobial mixtures | |
KR20130060084A (en) | Composition for preventing or treating peridontal disease | |
KR101834016B1 (en) | Composition for use in the oral cavity | |
KR102665309B1 (en) | Composition for prevention or treatment of oral disease comprising Cordycepin | |
HK1169035A (en) | Bad breath-removing agent |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
WWE | Wipo information: entry into national phase |
Ref document number: 201080029711.1 Country of ref document: CN |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 10799616 Country of ref document: EP Kind code of ref document: A1 |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
ENP | Entry into the national phase |
Ref document number: 20127003727 Country of ref document: KR Kind code of ref document: A |
|
122 | Ep: pct application non-entry in european phase |
Ref document number: 10799616 Country of ref document: EP Kind code of ref document: A1 |